Tetraphase Pharmaceuticals Stock Price - TTPH

-0.05 (-4.76%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Tetraphase Pharmaceuticals Inc TTPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.06 -5.41% 1.05 1.03 1.1589 1.13 1.11 19:26:51
Bid Price Ask Price Spread Spread % News
1.00 1.50 0.50 33.33% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
399 111,518 $ 1.10 $ 123,123 194,202 0.225 - 6.17
Last Trade Time Type Quantity Stock Price Currency
18:05:37 formt 2,800 $ 1.00 USD

Tetraphase Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 7.62M 7.26M $ -72.16M -22.75 - 6.88M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Tetraphase Pharmaceuticals News

Loading Messages....

Latest TTPH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TTPH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.872.000.851.42576,2390.1820.69%
1 Month1.752.000.561.27233,924-0.70-40.0%
3 Months2.773.860.562.01221,282-1.72-62.09%
6 Months5.345.800.562.57187,255-4.29-80.34%
1 Year1.316.170.2251.16366,928-0.26-19.85%
3 Years9.209.530.2253.58675,137-8.15-88.59%
5 Years36.6952.930.2257.03696,632-35.64-97.14%

Tetraphase Pharmaceuticals Description

Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is XERAVA (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.